ArticleCancer reports (Hoboken, N.J.)2026
NFIB Regulates Chemoresistance in Small Cell Lung Cancer by Suppressing Notch Signaling Activity.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSmall cell lung cancer (SCLC) is an aggressive malignancy characterized by the rapid development of therapy resistance, the underlying mechanisms of which remain incompletely understood. The transcription factor NFIB is a recognized oncogene in SCLC, promoting tumor progression by regulating metastasis and proliferation. However, its potential role in mediating chemotherapy resistance is poorly defined.
aimsThis study aimed to elucidate the mechanism by which NFIB regulates chemoresistance in SCLC and to assess the therapeutic potential of co-targeting NFIB and the Notch signaling pathway. METHODS AND
resultsExpression of NFIB and associated genes was analyzed in SCLC cell lines and clinical samples using Western blotting, quantitative real-time PCR (qRT-PCR), immunofluorescence (IF), and immunohistochemistry (IHC). Transcriptional regulation was examined by chromatin immunoprecipitation (ChIP), and drug sensitivity was measured via CCK-8 assays. We found that NFIB acts as a dual-function regulator, driving oncogenesis and controlling chemoresistance. NFIB knockdown activated the endogenous Notch pathway, which in turn promoted drug resistance. NFIB expression positively correlated with neuroendocrine (NE) markers and contributed to tumor heterogeneity, a process modulated by Notch1. Mechanistically, loss of NFIB relieved its repression of Notch1, leading to suppressed NE gene expression and yielding slow-cycling, chemoresistant cells with activated Notch signaling. Critically, combining Notch pathway inhibition with chemotherapy attenuated intratumoral heterogeneity and reversed this resistance phenotype.
conclusionsNFIB plays a paradoxical role in SCLC, serving as both an oncogenic driver and a key regulator of chemoresistance via Notch pathway activation. These findings revealed a novel resistance mechanism and propose a promising therapeutic strategy of combined Notch inhibition and chemotherapy for SCLC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.